BRCA2 and ovarian carcinoma: Extensive research throughout the last few decades has revealed that mutations in BRCA1 and BRCA2, encoding essential proteins in the HDR pathway, are a critical component of HDR impairment in hereditary and sporadic breast and ovarian carcinomas [2].